Matthias B. Jaffé
Nessuna posizione attualmente
Profilo
Matthias B.
Jaffé worked as the Chief Financial Officer and Director-Administration at Alantos Pharmaceuticals AG.
He also worked as the CFO and Vice President-Finance & Administration at Alantos Pharmaceuticals Holding, Inc. and as the Chief Financial Officer and VP-Business Development at Zafgen, Inc. Jaffé was the Chief Financial Officer at Pervasis Therapeutics, Inc. and Constellation Pharmaceuticals, Inc. He also worked as the Chief Financial & Accounting Officer at LogicBio Therapeutics, Inc. Jaffé received his undergraduate and graduate degrees from Massachusetts Institute of Technology and his MBA from INSEAD.
He received his undergraduate degree from Universidad Simón Bolívar.
Precedenti posizioni note di Matthias B. Jaffé
Società | Posizione | Fine |
---|---|---|
LOGICBIO THERAPEUTICS, INC. | Direttore Finanziario/CFO | 31/12/2020 |
CONSTELLATION PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 01/07/2017 |
LARIMAR THERAPEUTICS, INC. | Direttore Finanziario/CFO | 07/01/2013 |
Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. Medical SpecialtiesHealth Technology Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA. | Direttore Finanziario/CFO | 01/12/2011 |
Alantos Pharmaceuticals Holding, Inc.
Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Direttore Finanziario/CFO | 01/12/2007 |
Formazione di Matthias B. Jaffé
Massachusetts Institute of Technology | Graduate Degree |
INSEAD | Masters Business Admin |
Universidad Simón Bolívar | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 7 |
---|---|
Alantos Pharmaceuticals AG
Alantos Pharmaceuticals AG BiotechnologyHealth Technology Alantos Pharmaceuticals AG develops and manufactures molecule pharmaceuticals for arthritic and metabolic diseases. The company was founded in 1999 and is headquartered in Heidelberg, Germany. | Health Technology |
Alantos Pharmaceuticals Holding, Inc.
Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Health Technology |
YourBio Health, Inc.
YourBio Health, Inc. Electronic Equipment/InstrumentsElectronic Technology YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA. | Electronic Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. Medical SpecialtiesHealth Technology Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Matthias B. Jaffé